Journal article Open Access

Allopurinol pharmacogenetics: assessment of potential clinical usefulness

Zineh, Issam; Mummaneni, Padmaja; Lyndly, Jenna; Amur, Shashi; La Grenade, Lois A.; Chang, Stephen H.; Rogers, Hobart; Pacanowski, Michael A.

Dublin Core Export

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="" xmlns:oai_dc="" xmlns:xsi="" xsi:schemaLocation="">
  <dc:creator>Zineh, Issam</dc:creator>
  <dc:creator>Mummaneni, Padmaja</dc:creator>
  <dc:creator>Lyndly, Jenna</dc:creator>
  <dc:creator>Amur, Shashi</dc:creator>
  <dc:creator>La Grenade, Lois A.</dc:creator>
  <dc:creator>Chang, Stephen H.</dc:creator>
  <dc:creator>Rogers, Hobart</dc:creator>
  <dc:creator>Pacanowski, Michael A.</dc:creator>
  <dc:description>Use of pharmacogenetics to inform treatment decisions remains a priority for clinicians, patients and public health agencies. We previously developed a framework for systematically assessing whether pharmacogenetic test information would likely bring value to clinical decision-making and enjoy practical uptake. We applied this tool to allopurinol to determine potential usefulness of HLA genetic information in assessing risk for allopurinol-induced severe cutaneous adverse reactions. We quantified allopurinol use data and the magnitude of adverse event signals using US FDA databases, reviewed reported cases of allopurinol-associated severe cutaneous adverse reactions to assess whether clinical subtypes of patients could be identified, performed pooled analyses of associations between HLA variation and allopurinol-induced severe cutaneous adverse reactions and described considerations in clinical implementation of allopurinol pharmacogenetics.</dc:description>
  <dc:title>Allopurinol pharmacogenetics: assessment of potential clinical usefulness</dc:title>
Views 256
Downloads 176
Data volume 114.2 MB
Unique views 246
Unique downloads 169


Cite as